ATTRACTION-4

NCT02746796 📎

Regimen

Experimental
nivolumab + SOX or CAPOX
Control
placebo + SOX or CAPOX

Population

East Asian patients with HER2-negative advanced gastric/GEJ cancer as first-line therapy

Key finding

mPFS 10.45 vs 8.34 mo (HR 0.68, 98.51% CI 0.51-0.90, p=0.0007); mOS 17.45 vs 17.15 mo (HR 0.90, p=0.26, primary OS endpoint NOT met)

Source: PMID 35030335

Timeline

    Guideline citations

    • NCCN GASTRIC (p.38)
    • CSCO GASTRIC 2025 (p.97)⚠️ OCR source